Valuation : Veradermics, Incorporated

Market Cap 4.29B 3.69B 3.45B 3.16B 5.95B 410B 5.97B 40.87B 15.98B 207B 16.13B 15.78B 684B P/E 2026 *
-35.1x
P/E 2027 * -38.9x
Enterprise Value 4.29B 3.69B 3.45B 3.16B 5.95B 410B 5.97B 40.87B 15.98B 207B 16.13B 15.78B 684B EV / Sales 2026 *
-
EV / Sales 2027 * 496x
Free-Float
97.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Veradermics, Incorporated

1 day-0.11%
1 week-2.58%
Current month-2.29%
1 month-7.92%
3 months+2.47%
6 months+123.77%
1 week 93.81
Extreme 93.81
108.87
1 month 93.77
Extreme 93.77
117.4
Current year 32
Extreme 32
131.24
1 year 32
Extreme 32
131.24
3 years 32
Extreme 32
131.24
5 years 32
Extreme 32
131.24
10 years 32
Extreme 32
131.24
Manager TitleAgeSince
Chief Executive Officer 31 2022-11-30
President 36 2020-07-31
Director of Finance/CFO 40 2023-09-30
Director TitleAgeSince
Director/Board Member 31 2019-09-30
Director/Board Member 84 2021-08-31
Director/Board Member 75 2021-08-31
Date Insider Type Main position Quantity % Market Cap.
8/20/26
Montanova Capital LLC
OptionCompany 600,000 1.4361%
8/17/26 Fiscal year

Founder

50,404 0.1206%
8/17/26 Fiscal year

Founder

74,404 0.1781%
Change 5-day change 1-year change 3-year change Capi.($)
-0.11%-2.58% - - 4.29B
-0.49%-5.05%+60.94%+113.31% 1,060B
-1.24%-0.24%+50.88%+62.36% 651B
-1.76%-1.35%+24.14%+75.19% 465B
-1.17%-2.10%+38.61%+40.46% 365B
-2.00%-1.35%+22.22%+37.78% 300B
-0.98%+0.53%+2.04%+12.13% 258B
-0.10%+1.37%+52.69%+71.39% 238B
-3.18%-0.30%-17.23%-54.33% 210B
+0.12%+3.56%+30.39%+92.81% 184B
Average -1.03%-1.36%+29.41%+50.12% 373.47B
Weighted average by Cap. -1.04%-2.16%+38.79%+66.34%

Financials

2026 *2027 *
Net sales - 8.66M 7.43M 6.96M 6.37M 12M 827M 12.04M 82.39M 32.21M 417M 32.51M 31.8M 1.38B
Net income -107M -91.91M -86.05M -78.8M -148M -10.23B -149M -1.02B -398M -5.15B -402M -393M -17.06B -119M -102M -95.59M -87.53M -165M -11.36B -165M -1.13B -442M -5.73B -447M -437M -18.95B
Net Debt - -
Logo Veradermics, Incorporated
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Employees
37
Date Price Change Volume
26-08-27 US$102.88 +0.08% 119,665
26-08-26 US$102.80 +0.44% 657,047
26-08-25 US$102.35 +3.95% 787,163
26-08-24 US$98.46 -4.24% 717,278
26-08-21 US$102.82 -2.37% 393,617
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
102.80USD
Average target price
163.50USD
Spread / Average Target
+59.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MANE Stock